Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C

SpringerPlus

Table 3 Stepwise logistic regression analysis of the factors related to alpha fetoprotein > 5 ng/mL

	Univariate analysis		Multivariate analysis
Factors	Odds ratio (range^†)	p	Odds ratio (range^†)	p
Age (years)	1.0 (1.0-1.1)	0.0024	1.0 (1.0-1.1)	0.064
Sex (1:male)	0.95 (0.58-1.6)	0.84
Body mass index	1.2 (1.1-1.3)	0.0005	1.2 (1.1-1.3)	0.0006
Liver fibrosis	2.8 (1.9-4.2)	<0.0001
Hepatitis activity	1.1 (0.61-1.9)	0.83
Liver steatosis (1: >30%)	1.8 (1.1-3.0)	0.026	1.3 (0.72-2.4)	0.37
rs 8099917 of IL28B (1: TT)	1.1 (0.65-2.0)	0.67
rs738409 of PNPLA3 (1: 148 M)	0.36 (0.20-0.65)	0.0007	0.46 (0.22-0.93)	0.032
Amino acid 70 of HCV core (1: glutamine)	1.1 (0.58-2.2)	0.71
Alanine aminotransferase (1: >40 IU/L)	2.3 (1.6-3.3)	<0.0001	1.6 (1.0-2.4)	0.037
Platelet count (1: >1.5x10⁵/mm³)	0.33 (0.22-0.50)	<0.0001	0.34 (0.19-0.60)	0.0002
HOMA-IR	1.0 (0.97-1.1)	0.33

^†: 95% confidence interval; PNPLA3, patatin-like phospholipase domain-containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance.